REPLIGEN CORP (RGEN) Stock Fundamental Analysis
NASDAQ:RGEN - US7599161095 - Common Stock
122.32 USD
+0.15 (+0.12%)
122.32 USD
0 (0%)
RGEN gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 54 industry peers in the Life Sciences Tools & Services industry. While RGEN has a great health rating, there are worries on its profitability. RGEN is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
RGEN had positive earnings in the past year.
RGEN had a positive operating cash flow in the past year.
Of the past 5 years RGEN 4 years were profitable.
In the past 5 years RGEN always reported a positive cash flow from operatings.
1.2 Ratios
Looking at the Return On Assets, with a value of -0.48%, RGEN is in line with its industry, outperforming 59.26% of the companies in the same industry.
RGEN's Return On Equity of -0.67% is fine compared to the rest of the industry. RGEN outperforms 62.96% of its industry peers.
With a Return On Invested Capital value of 0.57%, RGEN perfoms like the industry average, outperforming 59.26% of the companies in the same industry.
RGEN had an Average Return On Invested Capital over the past 3 years of 2.65%. This is significantly below the industry average of 16.00%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.48% | ||
| ROE | -0.67% | ||
| ROIC | 0.57% |
ROA(3y)2.57%
ROA(5y)3.26%
ROE(3y)3.42%
ROE(5y)4.3%
ROIC(3y)2.65%
ROIC(5y)3.3%
1.3 Margins
The Operating Margin of RGEN (3.72%) is comparable to the rest of the industry.
In the last couple of years the Operating Margin of RGEN has declined.
RGEN has a Gross Margin (50.99%) which is in line with its industry peers.
RGEN's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 3.72% | ||
| PM (TTM) | N/A | ||
| GM | 50.99% |
OM growth 3Y-58.46%
OM growth 5Y-32.3%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.88%
GM growth 5Y-2.12%
2. Health
2.1 Basic Checks
RGEN has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
RGEN has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, RGEN has more shares outstanding
RGEN has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 5.76 indicates that RGEN is not in any danger for bankruptcy at the moment.
RGEN has a better Altman-Z score (5.76) than 87.04% of its industry peers.
RGEN has a debt to FCF ratio of 5.04. This is a neutral value as RGEN would need 5.04 years to pay back of all of its debts.
RGEN has a better Debt to FCF ratio (5.04) than 66.67% of its industry peers.
RGEN has a Debt/Equity ratio of 0.26. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.26, RGEN perfoms like the industry average, outperforming 51.85% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.26 | ||
| Debt/FCF | 5.04 | ||
| Altman-Z | 5.76 |
ROIC/WACC0.06
WACC10.07%
2.3 Liquidity
A Current Ratio of 8.59 indicates that RGEN has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 8.59, RGEN belongs to the top of the industry, outperforming 88.89% of the companies in the same industry.
RGEN has a Quick Ratio of 7.32. This indicates that RGEN is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 7.32, RGEN belongs to the top of the industry, outperforming 88.89% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.59 | ||
| Quick Ratio | 7.32 |
3. Growth
3.1 Past
RGEN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 39.32%, which is quite impressive.
Measured over the past 5 years, RGEN shows a small growth in Earnings Per Share. The EPS has been growing by 7.11% on average per year.
Looking at the last year, RGEN shows a very negative growth in Revenue. The Revenue has decreased by -11.36% in the last year.
RGEN shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 18.62% yearly.
EPS 1Y (TTM)39.32%
EPS 3Y-21.5%
EPS 5Y7.11%
EPS Q2Q%12.12%
Revenue 1Y (TTM)-11.36%
Revenue growth 3Y-1.83%
Revenue growth 5Y18.62%
Sales Q2Q%18.36%
3.2 Future
Based on estimates for the next years, RGEN will show a very strong growth in Earnings Per Share. The EPS will grow by 26.58% on average per year.
Based on estimates for the next years, RGEN will show a quite strong growth in Revenue. The Revenue will grow by 15.90% on average per year.
EPS Next Y16.2%
EPS Next 2Y22.73%
EPS Next 3Y24.82%
EPS Next 5Y26.58%
Revenue Next Year14.5%
Revenue Next 2Y14.18%
Revenue Next 3Y14.52%
Revenue Next 5Y15.9%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 75.04, RGEN can be considered very expensive at the moment.
RGEN's Price/Earnings is on the same level as the industry average.
The average S&P500 Price/Earnings ratio is at 27.17. RGEN is valued rather expensively when compared to this.
A Price/Forward Earnings ratio of 54.87 indicates a quite expensive valuation of RGEN.
The rest of the industry has a similar Price/Forward Earnings ratio as RGEN.
When comparing the Price/Forward Earnings ratio of RGEN to the average of the S&P500 Index (22.78), we can say RGEN is valued expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 75.04 | ||
| Fwd PE | 54.87 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of RGEN is on the same level as its industry peers.
RGEN's Price/Free Cash Flow is on the same level as the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 64.95 | ||
| EV/EBITDA | 53.19 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
A more expensive valuation may be justified as RGEN's earnings are expected to grow with 24.82% in the coming years.
PEG (NY)4.63
PEG (5Y)10.56
EPS Next 2Y22.73%
EPS Next 3Y24.82%
5. Dividend
5.1 Amount
RGEN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
122.32
+0.15 (+0.12%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners104.6%
Inst Owner Change-11.04%
Ins Owners0.51%
Ins Owner Change-0.27%
Market Cap6.88B
Analysts80.71
Price Target183.61 (50.11%)
Short Float %6.93%
Short Ratio4.38
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.95%
Min EPS beat(2)-6.83%
Max EPS beat(2)10.73%
EPS beat(4)3
Avg EPS beat(4)8.75%
Min EPS beat(4)-6.83%
Max EPS beat(4)25.89%
EPS beat(8)4
Avg EPS beat(8)7.57%
EPS beat(12)8
Avg EPS beat(12)8.61%
EPS beat(16)12
Avg EPS beat(16)12.23%
Revenue beat(2)2
Avg Revenue beat(2)1.69%
Min Revenue beat(2)1.23%
Max Revenue beat(2)2.15%
Revenue beat(4)2
Avg Revenue beat(4)0.11%
Min Revenue beat(4)-2.03%
Max Revenue beat(4)2.15%
Revenue beat(8)2
Avg Revenue beat(8)-0.75%
Revenue beat(12)3
Avg Revenue beat(12)-0.94%
Revenue beat(16)7
Avg Revenue beat(16)0.86%
PT rev (1m)-0.55%
PT rev (3m)-1.95%
EPS NQ rev (1m)3.72%
EPS NQ rev (3m)-3.25%
EPS NY rev (1m)0.35%
EPS NY rev (3m)0.64%
Revenue NQ rev (1m)3.53%
Revenue NQ rev (3m)5.45%
Revenue NY rev (1m)2.35%
Revenue NY rev (3m)2.46%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 75.04 | ||
| Fwd PE | 54.87 | ||
| P/S | 10.21 | ||
| P/FCF | 64.95 | ||
| P/OCF | 52.09 | ||
| P/B | 3.34 | ||
| P/tB | 12.71 | ||
| EV/EBITDA | 53.19 |
EPS(TTM)1.63
EY1.33%
EPS(NY)2.23
Fwd EY1.82%
FCF(TTM)1.88
FCFY1.54%
OCF(TTM)2.35
OCFY1.92%
SpS11.98
BVpS36.65
TBVpS9.63
PEG (NY)4.63
PEG (5Y)10.56
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.48% | ||
| ROE | -0.67% | ||
| ROCE | 0.9% | ||
| ROIC | 0.57% | ||
| ROICexc | 0.76% | ||
| ROICexgc | 2.86% | ||
| OM | 3.72% | ||
| PM (TTM) | N/A | ||
| GM | 50.99% | ||
| FCFM | 15.72% |
ROA(3y)2.57%
ROA(5y)3.26%
ROE(3y)3.42%
ROE(5y)4.3%
ROIC(3y)2.65%
ROIC(5y)3.3%
ROICexc(3y)3.74%
ROICexc(5y)4.93%
ROICexgc(3y)17.96%
ROICexgc(5y)N/A
ROCE(3y)4.23%
ROCE(5y)5.26%
ROICexcg growth 3Y-71.22%
ROICexcg growth 5Y-37.94%
ROICexc growth 3Y-63.64%
ROICexc growth 5Y-32.38%
OM growth 3Y-58.46%
OM growth 5Y-32.3%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.88%
GM growth 5Y-2.12%
F-Score4
Asset Turnover0.23
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.26 | ||
| Debt/FCF | 5.04 | ||
| Debt/EBITDA | 4.24 | ||
| Cap/Depr | 25.94% | ||
| Cap/Sales | 3.88% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 104.92% | ||
| Profit Quality | N/A | ||
| Current Ratio | 8.59 | ||
| Quick Ratio | 7.32 | ||
| Altman-Z | 5.76 |
F-Score4
WACC10.07%
ROIC/WACC0.06
Cap/Depr(3y)88.31%
Cap/Depr(5y)109.53%
Cap/Sales(3y)7.3%
Cap/Sales(5y)7.94%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)39.32%
EPS 3Y-21.5%
EPS 5Y7.11%
EPS Q2Q%12.12%
EPS Next Y16.2%
EPS Next 2Y22.73%
EPS Next 3Y24.82%
EPS Next 5Y26.58%
Revenue 1Y (TTM)-11.36%
Revenue growth 3Y-1.83%
Revenue growth 5Y18.62%
Sales Q2Q%18.36%
Revenue Next Year14.5%
Revenue Next 2Y14.18%
Revenue Next 3Y14.52%
Revenue Next 5Y15.9%
EBIT growth 1Y451.21%
EBIT growth 3Y-59.22%
EBIT growth 5Y-19.7%
EBIT Next Year72.43%
EBIT Next 3Y40.62%
EBIT Next 5Y37.42%
FCF growth 1Y10.02%
FCF growth 3Y45.03%
FCF growth 5Y27.02%
OCF growth 1Y-11.28%
OCF growth 3Y13.8%
OCF growth 5Y21.15%